JP2022553934A - 薬学的製剤 - Google Patents

薬学的製剤 Download PDF

Info

Publication number
JP2022553934A
JP2022553934A JP2022522825A JP2022522825A JP2022553934A JP 2022553934 A JP2022553934 A JP 2022553934A JP 2022522825 A JP2022522825 A JP 2022522825A JP 2022522825 A JP2022522825 A JP 2022522825A JP 2022553934 A JP2022553934 A JP 2022553934A
Authority
JP
Japan
Prior art keywords
particle size
compound
size distribution
niclosamide
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022522825A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553934A5 (https=
Inventor
ゲーリー ディー． グリック
ジュニア アンソニー ダブリュー． オピパリ
Original Assignee
ファースト ウェーブ バイオ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファースト ウェーブ バイオ インコーポレイテッド filed Critical ファースト ウェーブ バイオ インコーポレイテッド
Publication of JP2022553934A publication Critical patent/JP2022553934A/ja
Publication of JP2022553934A5 publication Critical patent/JP2022553934A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2022522825A 2019-10-18 2020-10-16 薬学的製剤 Pending JP2022553934A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962923290P 2019-10-18 2019-10-18
US62/923,290 2019-10-18
PCT/US2020/056027 WO2021076922A1 (en) 2019-10-18 2020-10-16 Pharmaceutical formulations

Publications (2)

Publication Number Publication Date
JP2022553934A true JP2022553934A (ja) 2022-12-27
JP2022553934A5 JP2022553934A5 (https=) 2023-10-24

Family

ID=75492817

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022522825A Pending JP2022553934A (ja) 2019-10-18 2020-10-16 薬学的製剤

Country Status (9)

Country Link
US (1) US20210114973A1 (https=)
EP (1) EP4045480A4 (https=)
JP (1) JP2022553934A (https=)
KR (1) KR20240039083A (https=)
CN (1) CN117597327A (https=)
AR (1) AR122323A1 (https=)
CA (1) CA3157861A1 (https=)
TW (1) TW202128610A (https=)
WO (1) WO2021076922A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3338783B1 (en) 2014-09-12 2024-01-24 UNION therapeutics A/S Antibacterial use of halogenated salicylanilides
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
PE20181295A1 (es) 2015-09-01 2018-08-07 First Wave Bio Inc Metodos y composiciones para tratar afecciones asociadas a una respuesta inflamatoria anomala
GB201604484D0 (en) 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
WO2021174024A1 (en) * 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
US11045434B1 (en) 2020-04-01 2021-06-29 UNION therapeutics A/S Niclosamide formulations for treating disease
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
CN113768937B (zh) * 2021-11-15 2022-04-08 恒翼生物医药科技(上海)有限公司 用于降低尿酸水平的化合物
GB202301306D0 (en) * 2023-01-30 2023-03-15 Ucl Business Ltd Treatment of granulomatous disease
CN117357523A (zh) * 2023-10-25 2024-01-09 澳门大学 利拉萘酯在制备预防和治疗肺纤维化药物中的用途
CN117466786A (zh) * 2023-12-25 2024-01-30 湖南一格制药有限公司 盐酸戊乙奎醚杂质及其制备方法
WO2025207484A1 (en) * 2024-03-25 2025-10-02 Merveille.Ai Use of aprepitant and cyclic dipeptide for weight control
CN118649135B (zh) * 2024-07-18 2024-12-10 广东药科大学 一种缓解高尿酸血症肾病进程的药物制剂及其制备方法
CN119525016B (zh) * 2024-12-24 2026-04-07 中国矿业大学 一种组合捕收剂及其在钾长石反浮选脱硅中的应用
CN119431243B (zh) * 2025-01-09 2025-06-10 万邦德制药集团有限公司 一种氘代石杉碱甲化合物或其药学上可接受的盐及其制备方法和应用
CN119841970B (zh) * 2025-01-23 2026-02-27 集美大学 一种具有抗炎活性的乙酰化卡拉胶及其制备方法和应用
CN121406752A (zh) * 2025-12-26 2026-01-27 圣湘生物科技股份有限公司 粘性生物样本的液化组合产品、核酸检测试剂盒及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1527638A (en) * 1975-12-20 1978-10-04 Bayer Ag Niclosamide suspension formulations
GB2213722A (en) * 1988-01-15 1989-08-23 Ancare Distributors Anthelmintic niclosamide compositions.
JP2018529762A (ja) * 2015-09-01 2018-10-11 ファースト ウェーブ バイオ インコーポレイテッド 異常炎症反応に関連する状態を処置するための方法および組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003249244A1 (en) * 2002-07-15 2004-02-02 Combinatorx, Incorporated Methods for the treatment of neoplasms
CN1546919A (zh) * 2003-07-13 2004-11-17 叶声羽 桑拿浴房
CN1626506A (zh) * 2004-08-10 2005-06-15 李志良 高纯度、高收率氯硝柳胺的制备
EP2123626A1 (en) * 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
CN103751854B (zh) * 2014-01-20 2015-08-26 瞿介明 抗菌医用导管
EP3168211A1 (en) * 2015-11-10 2017-05-17 Westfälische Wilhelms-Universität Münster Pharmaceutical co-crystals of niclosamide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1527638A (en) * 1975-12-20 1978-10-04 Bayer Ag Niclosamide suspension formulations
GB2213722A (en) * 1988-01-15 1989-08-23 Ancare Distributors Anthelmintic niclosamide compositions.
JP2018529762A (ja) * 2015-09-01 2018-10-11 ファースト ウェーブ バイオ インコーポレイテッド 異常炎症反応に関連する状態を処置するための方法および組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JIAN-RONG DAI, ET AL.: "A novel molluscicidal formulation of niclosamide", PARASITOL RES, vol. 103, JPN6025008566, 2008, pages 405 - 412, XP019630961, ISSN: 0005670410 *

Also Published As

Publication number Publication date
TW202128610A (zh) 2021-08-01
AR122323A1 (es) 2022-08-31
CA3157861A1 (en) 2021-04-22
WO2021076922A1 (en) 2021-04-22
CN117597327A (zh) 2024-02-23
EP4045480A4 (en) 2023-11-22
EP4045480A1 (en) 2022-08-24
KR20240039083A (ko) 2024-03-26
US20210114973A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
JP7189983B2 (ja) 異常炎症反応に関連する状態を処置するための方法および組成物
US11564896B2 (en) Methods of treatment
JP2022553934A (ja) 薬学的製剤
WO2021188564A1 (en) Methods of treating covid-19 with a niclosamide compound
US20230102999A1 (en) Deuterated niclosamide

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231013

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231013

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250303

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250825